CCL2 and Stroke: In SHRSP, fed a high-salt diet, rosuvastatin treatment significantly delayed the onset of stroke and attenuated the transcription of inflammatory biomarkers (MCP-1, TGF-β1, IL-1β, and TNF-α) [57].